BRCA2 and ovarian carcinoma: Finally, Blanco and colleagues [76] recently screened a large series of 516 BRCA1/BRCA2-negative patients from breast and/or ovarian cancer families for RAD51C mutations and identified 3 germline pathogenic mutations.